Olema Pharmaceuticals (OLMA): Reassessing Valuation After S&P Biotechnology Select Industry Index Inclusion

Olema Pharmaceuticals (OLMA) just earned a spot in the S&P Biotechnology Select Industry Index, a milestone that can quietly reshape its shareholder base as index funds and biotech-focused investors take a closer look.

See our latest analysis for Olema Pharmaceuticals.

That index inclusion caps a wild run for Olema, with the share price at $28.18 after a 30 day share price return of 21.62 percent and a 90 day surge of 220.59 percent. The 1 year total shareholder return of 347.30 percent hints that momentum, not just sentiment, has been building for some time despite volatility around events like its recent universal shelf registration.

If Olema’s move has you rethinking what is possible in healthcare, this could be a good moment to explore other promising healthcare stocks that might be earlier in their journey.

With Olema still trading at a steep discount to Wall Street’s target despite a blistering rally, the real question now is whether investors are staring at an overlooked value or a stock already pricing in years of growth.

Price to Book of 7.2x: Is it justified?

At a last close of $28.18, Olema trades on a rich price to book ratio of 7.2 times, signaling a market that is already baking in aggressive expectations compared to peers.

The price to book multiple compares Olema’s market value to the net assets on its balance sheet, a common yardstick for development stage biotechs that have little or no revenue. A high figure like this often reflects confidence that future clinical milestones and eventual commercialization will create value far beyond today’s accounting equity.

That optimism comes with tension, as Olema remains unprofitable, is forecast to stay loss making over the next three years, and carries a negative return on equity. Against that backdrop, paying more than seven times book value suggests investors are effectively pre paying for years of anticipated progress, with limited room for disappointment if revenue growth or trial results lag expectations.

The comparison with the broader space is stark. Olema’s 7.2 times price to book multiple is far above both the 2.6 times biotech industry average and the 4.2 times peer group level. Such a premium valuation implies the market views Olema as a potential standout rather than a typical biotech. Any shift in sentiment could see that gap narrow quickly, in either direction.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 7.2x (OVERVALUED)

However, Olema’s zero revenue and ongoing losses mean any delay or setback in pivotal palazestrant trials could quickly puncture confidence and compress its valuation.

Find out about the key risks to this Olema Pharmaceuticals narrative.

Build Your Own Olema Pharmaceuticals Narrative

If you see the story differently or want to stress test the numbers yourself, you can build a custom view in just minutes: Do it your way

A great starting point for your Olema Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Olema might be a standout, but letting this be your only idea could mean missing out on other powerful opportunities quietly compounding away on Simply Wall Street.

• Capitalize on underappreciated value by using these 898 undervalued stocks based on cash flows to spot companies where market pessimism clashes with strong underlying cash flows.
• Target future growth engines with these 24 AI penny stocks, focusing on businesses building real revenue around AI rather than just riding the hype.
• Lock in potential income streams through these 10 dividend stocks with yields > 3% and pinpoint companies offering attractive yields backed by resilient balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com